Literature DB >> 12814690

Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder.

H Schulte-Baukloh1, Th Michael, B Stürzebecher, H H Knispel.   

Abstract

OBJECTIVES: Children with neurogenic hyper-reflexive bladder in whom classical therapy with anticholinergic drugs and intermittent catheterization fails are threatened by high intravesical pressure, vesicoureteral reflux, and impairment of kidney function. Surgery, such as bladder augmentation, is often necessary in such cases. To obviate surgery in these high-risk children, we investigated the use of detrusor injection of botulinum-A toxin (Botox).
METHODS: Our subjects were 20 children with hyper-reflexive detrusor muscle and high bladder pressure, over 40 cmH(2)O despite anticholinergic therapy. After baseline urodynamic measurements, we injected botulinum-A toxin into the detrusor muscle at 30-50 sites at 12 U/kg of body weight up to a maximum of 300 U. Follow-up cystometric measurements were taken two to four weeks and three and six months after injection.
RESULTS: From basic measurements to follow-up cystometry, mean reflex volume changed from 97.1 ml before injection to 178.6 ml after four weeks (p<0.01) and to 162.8 ml after three months (p<0.01). After six months mean reflex volume returned to 119.3 ml (n.s.). Maximal bladder capacity changed from 163.1 ml to 219.9 ml (p<0.01), to 200.6 ml (p<0.01) and to 222.4 ml (p<0.01), respectively, and maximal detrusor pressure changed from 59.6 cmH(2)O to 34.9 cmH(2)O (p<0.01), to 46.7 cmH(2)O (n.s.) and to 61.8 cmH(2)O (n.s.), respectively.
CONCLUSION: Botulinum-A toxin (Botox) is effective when injected into the hyper-reflexive detrusor muscle. It is a valuable treatment option in the management of neurogenic bladder. The effect lasts about six months, and then reinjection is necessary.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12814690     DOI: 10.1016/s0302-2838(03)00136-2

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  27 in total

Review 1.  [Botulinum toxin in urology. Indications and results].

Authors:  B Schurch; A Reitz
Journal:  Urologe A       Date:  2004-11       Impact factor: 0.639

Review 2.  [Botulinum toxin for the treatment of neurogenic detrusor hyperactivity. Consensus paper on use for neurogenic bladder dysfunction].

Authors:  K-D Sievert; J Bremer; H Burgdörfer; B Domurath; C Hampel; J Kutzenberger; C Seif; M Stöhrer; B Wefer; J Pannek
Journal:  Urologe A       Date:  2007-03       Impact factor: 0.639

3.  [Seven years of botulinum toxin type A in the treatment of neurogenic detrusor hyperactivity].

Authors:  M Stöhrer; A Wolff; G Kramer; R Steiner; D Löchner-Ernst; D Leuth; U Steude; H Rübben
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

4.  Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system.

Authors:  Dirk Dressler
Journal:  J Neurol       Date:  2012-08-10       Impact factor: 4.849

5.  Systematic review of therapy for neurogenic detrusor overactivity.

Authors:  Clare J Fowler
Journal:  Can Urol Assoc J       Date:  2011-10       Impact factor: 1.862

6.  Urinary incontinence in children: botulinum toxin is a safe and effective treatment option.

Authors:  Dermot Thomas McDowell; Damien Noone; Farhan Tareen; Mary Waldron; Feargal Quinn
Journal:  Pediatr Surg Int       Date:  2012-01-15       Impact factor: 1.827

Review 7.  Botulinum toxin in paediatric urology: a systematic literature review.

Authors:  Ranan DasGupta; Feilim Liam Murphy
Journal:  Pediatr Surg Int       Date:  2008-10-25       Impact factor: 1.827

Review 8.  Medical Management of Neurogenic Bladder for Children and Adults: A Review.

Authors:  Elizabeth Lucas
Journal:  Top Spinal Cord Inj Rehabil       Date:  2019

9.  Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity.

Authors:  Ibrahim Fathi Ghalayini; Mohammed A Al-Ghazo; Ziad Ali Elnasser
Journal:  Int Urol Nephrol       Date:  2009-01-31       Impact factor: 2.370

Review 10.  [Botulinum toxin in urology. An inventory].

Authors:  H Schulte-Baukloh; H H Knispel
Journal:  Urologe A       Date:  2004-08       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.